ReviewMarine drugs2025
The Deep Mining Era: Genomic, Metabolomic, and Integrative Approaches to Microbial Natural Products from 2018 to 2024.
Review in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Biosynthetic Diversity of Marine-DerivedMarine drugs · 2026Review
- Endophytic Fungal Metabolites as Modulators of Key Signaling Pathways in Chronic Diseases and Aging.Antibiotics (Basel, Switzerland) · 2026Review
- Review
- Marine-derived Peptides As Anti-biofilm and Anti-virulence Agents: Mechanistic Insights and Applications Against Microbial Pathogens.Probiotics and antimicrobial proteins · 2026Review
- The Incredible Potential of Cave Actinobacteria in Finding New Antimicrobials and Bioactive Compounds.Chemistry & biodiversity · 2026Review
- 2-Hydroxy-4-Methoxybenzaldehyde (2H4MB): Integrating Cell Culture, Metabolic Engineering, and Intelligent Genome Editing.International journal of molecular sciences · 2026Review
- Editorial: Novel natural therapies for infectious diseases using computational and pharmacological approaches.Frontiers in pharmacology · 2026Article
- Microbial engineering for pesticide degradation: current insights and future directions for sustainable agriculture.Frontiers in microbiology · 2026Review
- Anticancer natural products from the Middle East and North Africa: biodiversity, mechanisms, and translational challenges.Frontiers in oncology · 2026Review
- Sulfur-Containing Microbial Natural Products and Their Role in Communal Interactions.Journal of natural products · 2025Review
- Whole genome surveying and metabolomic profiling aided navigation of therapeutic plethora of Streptomyces melanogenes WPF1 isolated from Pinus patula rhizosphere.Bioresources and bioprocessing · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Over the past decade, microbial natural products research has witnessed a transformative "deep-mining era" driven by key technological advances such as high-throughput sequencing (e.g., PacBio HiFi), ultra-sensitive HRMS (resolution ≥ 100,000), and multi-omics synergy. These innovations have shifted discovery from serendipitous isolation to data-driven, targeted mining. These innovations have transitioned discovery from serendipitous isolation to data-driven targeted mining. Genome mining pipelines (e.g., antiSMASH 7.0 and DeepBGC) can now systematically discover hidden biosynthetic gene clusters (BGCs), especially in under-explored taxa. Metabolomics has achieved unprecedented accuracy, enabling researchers to target novel compounds in complex extracts. Integrated strategies-combining genomic prediction, metabolomics analysis, and experimental validation-constitute new paradigms of current "deep mining". This review provides a systematic overview of 185 novel microbial natural products discovered between 2018 and 2024, and dissects how these technological leaps have reshaped the discovery paradigm from traditional isolation to data-driven mining.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.